Oriental Baitai’s anti-cancer drug has received clinical trial approval!
[Summary Description]
Beijing Dongfang Baitai Biotechnology Co., Ltd. is an emerging biotechnology company focused on the research and development of humanized monoclonal antibodies. Its investigational product, the anti-VEGF humanized antibody JY028, recently received approval from the China Food and Drug Administration (CFDA) to proceed with clinical trials, marking a significant milestone that allows Dongfang Baitai to officially initiate clinical studies in China and take an important step toward product commercialization. This achievement also represents another major breakthrough for Dongfang Baitai, following its earlier receipt of clinical trial authorization for the long-acting diabetes biologic JY09.
Beijing Dongfang Baitai Biotechnology Co., Ltd. is an emerging biotechnology company focused on the research and development of humanized monoclonal antibodies. Its investigational product, the anti-VEGF humanized antibody JY028, recently received approval from the China Food and Drug Administration (CFDA) to proceed with clinical trials, marking a significant milestone that allows Dongfang Baitai to officially initiate clinical studies in China and take an important step toward product launch. This achievement also represents another major breakthrough for Dongfang Baitai, following its earlier receipt of clinical trial authorization for the long-acting diabetes biologic JY09.
01. About JY028
Biosimilar drug
JY028 is a vascular endothelial growth factor (VEGF) inhibitor and is classified as a biosimilar.
Mechanism of action
It can specifically bind to VEGF, thereby blocking VEGF’s interaction with its receptors (Flt-1 and KDR) on endothelial cells, and inhibiting tumor angiogenesis, tumor growth, and metastasis.

Mechanism of Action Diagram for JY028
Indications
The approved indications for this drug are metastatic colorectal cancer and non-small cell lung cancer.
02. Regarding the originator drug bevacizumab, JY028
Domestic and International Research and Market Status of the Drug
The original investigational drug for JY028, bevacizumab (Avastin), was developed by Genentech, a subsidiary of Roche, and is the world’s first anti-angiogenic agent.
It received its first approval from the U.S. Food and Drug Administration (FDA) in February 2004.
Approved by the European Medicines Agency (EMA) in January 2005;
In August 2007, it received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan.
It was approved for marketing by the China Food and Drug Administration (CFDA) in February 2010.
It has currently been approved for the treatment of cancer in more than 120 countries.
Since 2012, bevacizumab has consistently ranked among the top ten best-selling single-agent therapies worldwide. In 2016, its sales approached US$7 billion, placing it sixth on the global list of best-selling single agents and fourth on the global antibody‑drug ranking. It enjoys strong performance in international markets and boasts substantial market potential in China.
Numerous indications
Since its first approval in the United States in 2004, bevacizumab has been approved internationally for the treatment of metastatic colorectal cancer, non–small cell lung cancer, malignant gliomas, cervical cancer, and recurrent ovarian, fallopian tube, or primary peritoneal cancers, encompassing a wide range of solid tumors.
The patent is about to expire.
Bevacizumab has entered the Chinese market and has been approved for the treatment of metastatic colorectal cancer and non‑small cell lung cancer. With its patent set to expire in 2019, it has become one of the most sought‑after targets for biosimilar development in China.
03.JY028 Huge market demand
The number of patients is large.
The number of newly diagnosed cancer cases in China has been increasing year by year; in 2015 alone, there were over 4 million new cases of invasive cancer and more than 2.8 million cancer-related deaths. Lung cancer, colorectal cancer, kidney cancer, and breast cancer are among the most common malignancies and also rank first among causes of cancer mortality.

Imported drugs are expensive.
At present, most targeted therapies for the aforementioned solid tumors in China are imported from abroad, and their high costs impose a significant financial burden on cancer patients.
There is an urgent need for domestically produced drugs.
With the gradual expiration of domestic and international patents, bevacizumab has become one of the most sought-after targets for biosimilar development, both in China and worldwide. Riding the wave of the booming biosimilar market, the successive launch of biosimilar products based on this molecule will bring benefits to an increasing number of patients.
Oriental Baitai boasts a leading team in antibody drug research and development and manufacturing. Its JY028 demonstrates high similarity to bevacizumab, with experimental data showing excellent efficacy and safety profiles. While expanding into the domestic market, the JY028 program also targets the global arena, leveraging strong cooperative ties with South American countries to tap into the vast South American market. We are confident that, in the fiercely competitive biosimilars landscape, JY028 will secure a distinct and compelling position.
04. About Dongfang Baitai
Beijing Dongfang Baitai Biotechnology Co., Ltd. is located in the Yizhuang Park of Zhongguancun, covering an area of nearly 60,000 square meters. It is a high-tech enterprise specializing in the innovative research, development, and production of antibodies, with a primary focus on novel therapeutic and preventive biopharmaceuticals for major diseases.
The company boasts an international, multidisciplinary antibody R&D team of over one hundred professionals and has established a cutting-edge, end-to-end industrialization platform centered on innovative antibody therapeutics and next-generation vaccines. With nearly 20 pipeline programs spanning oncology, diabetes, autoimmune diseases, and other therapeutic areas, the company anticipates receiving clinical trial approval for a major antibody drug in 2017, while simultaneously filing clinical applications for two to three additional candidates. Dongfang Baitai remains committed to making significant contributions to the prevention and treatment of major diseases in China, as well as to accelerating the country’s biopharmaceutical innovation and industrialization.
A warm welcome to Vice Mayor Lin Keqing for his visit and guidance at Dongfang Baitai.
On October 24, 2016, Beijing Vice Mayor Lin Keqing and his delegation visited Beijing Dongfang Baitai Biotechnology Co., Ltd. and Baitai Bio-pharmaceutical Co., Ltd., conducted an in-depth review of the companies’ R&D progress, inspected the production workshops on-site, and engaged in cordial discussions.
Leave a Message Online Online Message